Sefaxersen Hits Primary Endpoint in Phase 3 IgA Nephropathy Trial, Opening Path to Accelerated Approval
- Sefaxersen, Ionis's antisense oligonucleotide suppressing liver complement factor B, met the primary endpoint of Roche's Phase 3 IMAgINATION trial in high-risk primary IgA nephropathy.
- A prespecified interim analysis of 459 patients (1:1 randomized) showed statistically significant, clinically meaningful proteinuria reduction (24-hour UPCR) vs. placebo at week 37.
- The once-monthly, self-administered subcutaneous drug could support accelerated approval in a crowded IgAN market that already includes sparsentan.
💡 Points
Complement factor B suppression becomes a third distinct mechanism validated in IgA nephropathy, joining sparsentan's endothelin/AT1 blockade and the B-cell/APRIL plays from atacicept and sibeprenlimab; convergent proteinuria data across mechanisms suggests the market fragments by dosing convenience, not efficacy. Once-monthly self-injection undercuts daily oral and infused rivals on adherence, while Ionis banks another platform-licensing win validating its originate-and-out-license model.
Roche kidney drug's Phase 3 win sets up path to accelerated approval ↗